Home > Riviste > International Angiology > Fascicoli precedenti > International Angiology 2006 December;25(4) > International Angiology 2006 December;25(4):414-7

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

INTERNATIONAL ANGIOLOGY

Rivista di Angiologia


Official Journal of the International Union of Angiology, the International Union of Phlebology and the Central European Vascular Forum
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,37


eTOC

 

Original articles  


International Angiology 2006 December;25(4):414-7

Copyright © 2006 EDIZIONI MINERVA MEDICA

lingua: Inglese

The effect of fluvastatin on cICAM-1 as a biomarker of endothelial dysfunction in patients with dyslipidemia

Sejda T. 1, Jedlièková V. 1, Svandová E. 2, Poledne R. 3

1 Department of Internal Medicine I, Thomayer University Hospital, Prague, CzechRepublic 2 National Health Institute, Prague, Czech Republic 3 Institute for Clinical and Experimental Medicine, Prague, Czech Republic


PDF  


Aim. Upregulation of intercellular adhesion molecule-1 (ICAM-1) expression has been suggested to play an important role in the pathogenesis of atherosclerosis. Lipid-lowering therapy with 3-hydroxy-methylglutaryl-coenzyme A reductase inhibitors reduces the incidence of atherosclerosis-related cardiovascular events. The aim of this study was to establish the effect of a 3-month treatment of fluvastatin on circulating (c)ICAM-1 and standard lipid parameters.
Methods. A total of 14 patients (6 men and 8 women), 59.7±11 years old, with mean systolic and diastolic blood pressure 135±16.3 and 81±9.3 mmHg, respectively, fasting plasma cholesterol 6.2±1 mmol/L and plasma triglycerides 2.6±1 mmol/L, took part in the study. The observed parameters were measured before and after 3 months of therapy.
Results. When comparing total cholesterolemia, low-density lipoprotein (LDL) cholesterol, and apolipoprotein B, there were significant decreases after a 3-month treatment. By contrast, no significant difference was observed when we compared the values of triglycerides, high-density lipoprotein (HDL) cholesterol, apolipoprotein A1 and, especially, of cICAM-1. Our results demonstrate the well-known capacity of fluvastatin to lower LDL- and total cholesterol; however, it failed to reduce cICAM after a 3-month treatment.
Conclusions. It can be concluded that a 3-month therapy with fluvastatin does not decrease cICAM-1 levels, despite normalization of cholesterol levels. The implication is that cholesterol may not induce endothelial activation by the initial upregulation of this adhesive molecule.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail